Roche's divarasib reduced death risk by 44% in KRAS G12C lung cancer, outperforming existing drugs in a head-to-head trial.

HER2-positive breast cancer chemotherapy can be safely omitted in about 30% of patients, five-year PHERGain trial data ...

Diagnostic and surgical approaches to treating the disease are evolving — just as rates are spiking. Learn how the surgical ...

By Nancy Lapid Oct 30 (Reuters) - Today we report on a troubling cancer trend among US adults of all ages. We also report on ...

Today we report on a troubling cancer trend among US adults of all ages. We also report on impressive survival data from a ...

OPTIMA shows Prosigna assay can help many ER-positive, HER2-negative breast cancer patients safely avoid chemotherapy.

High-dose omega-3 fatty acid supplements might improve survival among some patients with advanced colon cancer, a new study ...

Interest in pancreatic health has been growing amid the recent boom in obesity drugs such as Wegovy and Mounjaro, but the ...

Intensified adjuvant chemotherapy did not improve disease-free survival (DFS) compared with standard chemotherapy in patients ...

Single-agent immunotherapy as first-line treatment led to a huge improvement in progression-free survival (PFS) in inoperable recurrent/advanced mismatch repair-deficient (dMMR) endometrial cancer, a ...

KEYNOTE-B49 data show pembrolizumab plus chemotherapy improved PFS but not OS in PD-L1–positive HR+/HER2– advanced breast ...

A retrospective Chinese study reports that all 11 patients with lymph-node-dominant metastatic gallbladder cancer responded ...